ClinicalTrials.gg
CompletedNCT01870388Updated Jun 6, 2017Results posted

A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

A Phase 1 interventional study of Baricitinib in Liver Diseases and Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Primary conditionHepatic InsufficiencyRegistry: Liver DiseasesReclassifiedWhy we changed it
Registry
Liver Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatic Insufficiency
Why
  1. The study's listed conditions name Hepatic Insufficiency, a narrower term within Liver Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.

Enrollment
12th of 12
16 · median 34
Started
2013
with 1 other
Phase 1
12 of 12
2 open now
Registered
3rd of 12
by date

Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 12th largest by enrollment, is one of 2 that started in 2013, is one of 12 in phase 1, and was the 3rd registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hepatic Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including screening.

03

Conditions studied

  • Liver Diseases
  • Hepatic Insufficiency

Browse trials for

04

In context

Hepatic Insufficiency Reclassified

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

This study's enrollment of 16 is below the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.

Browse Hepatic Insufficiency studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Hepatic Insufficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants agree to use 2 reliable methods of with female partners of during the study and for at least 3 months following the last dose of study drug
  • Women not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks after confirmed tubal occlusion/tubal ligation) confirmed by medical history or menopause
  • Menopausal women with spontaneous amenorrhea for at least 12 months, not induced by a medical condition and by medications and have a follicle-stimulating hormone (FSH) level greater than 40 milli-international units per milliliter (mIU/mL) (unless the participant is taking hormone replacement therapy [HRT])
  • Have a of 18.5 to 40.0 kilograms per square meter (kg/m\^2) inclusive at the time of screening

Additional Inclusion Criteria for Healthy Participants:

  • Are overtly healthy participants, have normal hepatic function and have stable chronic medical conditions
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator

Additional Inclusion Criteria for Hepatically Impaired Participants:

  • Participants with hepatic impairment classified as score A or B (mild [Group 3, if enrolled] or moderate [Group 2] impairment, respectively). Must have a diagnosis of chronic hepatic impairment (greater than 6 months), with no clinically significant changes within 90 days prior to study drug administration (Day 1). Participants may have mild stable baseline medical conditions for which neither the condition nor treatments received would negatively impact the health of the participant or study conduct
  • Clinical laboratory test results with deviations that are judged by the investigator to be compatible with the hepatic impairment of the participant, or of no additional clinical significance for this study

Exclusion criteria

Exclusion Criteria for ALL Participants:

  • Have received, within the last 30 days, an product as part of a clinical trial, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Persons who have previously completed or withdrawn from study investigating baricitinib, and have previously received the investigational product
  • Women with a positive pregnancy test or who are lactating
  • Have a current or recent history (less than 30 days prior to screening and/or less than 45 days prior to admission to the clinical research unit) of a bacterial, fungal, parasitic, viral (excluding rhinopharyngitis), or mycobacterial infection
  • Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Have been exposed to a within 12 weeks prior to the first dose or expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study

Additional Exclusion Criteria for Healthy Participants:

  • Show evidence of acute or chronic liver disease
  • Show evidence of and/or positive hepatitis B and/or positive hepatitis B surface antigen
  • Show evidence of and/or positive hepatitis C antibody
  • Intend to use over-the-counter or prescription medication and/or herbal supplements within 14 days prior to dosing and during the study

Additional Exclusion Criteria for Liver Impaired Participants:

  • Have less than or equal to 50 milliliter per minute (mL/min) using the Cockcroft and Gault formula
  • Show evidence of spontaneous bacterial peritonitis within 6 month of dosing
  • Have had variceal bleeding within 3 months of check in
  • Show evidence of severe hyponatremia (sodium less than 120 millimolar per liter (mmol/L)
  • Have severe encephalopathy (Grade 3 to 4)
  • Have moderate to severe ascites (moderately hepatically impaired participants only)
  • Show presence of a portal shunt
  • Have less than 9.0 grams per deciliter (g/dL)
  • Have serum greater than 15 milligrams per deciliter (mg/dL)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Baricitinib (Healthy)

    Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.

    Drug: Baricitinib

  • Experimental
    Baricitinib (Moderate)

    Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.

    Drug: Baricitinib

  • Experimental
    Baricitinib (Mild)

    Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.

    Drug: Baricitinib

Interventions

  • Administered orally

    Also known as: LY3009104

07

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib (LY3009104)

    Time frame: Predose up to 48 hours (h) postdose

  2. PK: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)] of Baricitinib

    Time frame: Predose up to 48 h postdose

08

Results

Posted Apr 21, 2017

Participant flow

Participant flow — Overall Study
MilestoneBaricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)
Started88
Received 1 dose of study drug88
Completed88
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib (LY3009104)
Time frame:
Predose up to 48 hours (h) postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib (LY3009104)
nanograms per milliliter (ng/mL)Baricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib (LY3009104)35.3 ± 2538.2 ± 23
PrimaryPK: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)] of Baricitinib
Time frame:
Predose up to 48 h postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)] of Baricitinib
nanograms*hour/milliliter (ng*h/mL)Baricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity [AUC(0-∞)] of Baricitinib295 ± 25350 ± 28

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib (Healthy Participants)—0/8 (0%)2/8 (25%)
Baricitinib (Moderate Hepatic Impairment)—0/8 (0%)4/8 (50%)
Most frequent other events
Most frequent other events
EventBaricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)
NauseaGastrointestinal disorders0/81/8
Neutrophil count decreasedInvestigations0/81/8
DizzinessNervous system disorders1/81/8
HeadacheNervous system disorders1/81/8

Baseline characteristics

All enrolled participants.

Age, Categorical
Age, Categorical(Participants)Baricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)Total
<=18 years000
Between 18 and 65 years6814
>=65 years202
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)Total
Female112
Male7714
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)Total
Hispanic or Latino538
Not Hispanic or Latino358
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White7815
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Baricitinib (Healthy Participants)Baricitinib (Moderate Hepatic Impairment)Total
United States8816
09

Study locations

2 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33014, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32806, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2013
First posted
Jun 6, 2013
Start
Jun 2013
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Apr 21, 2017
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01870388
Responsible party
Sponsor
First posted
Jun 6, 2013
Start date
Jun 2013
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Apr 21, 2017
Last update
Jun 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion